Inactive Instrument

Company Zalicus Inc Nasdaq

Equities

US98887C1053

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2018	Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	CI
2018	Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q).	CI

Business Summary

EPIRUS Biopharmaceuticals, Inc. is in bankruptcy.

Sales per Business

USD in Million	2014	Weight	2015	Weight	Delta
Biopharmaceutical 100.0 %	0	100.0 %	1	100.0 %	+17,425.00%

Sales per region

USD in Million	2014	Weight	2015	Weight	Delta
United States 100.0 %	0	100.0 %	1	100.0 %	+17,425.00%

Share class

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	26,184,349	26,184,349 ( 100.00 %)	0	100.00 %

Shareholders

Name	Equities	%	Valuation
Pender Private Equity Fund Management, Inc. 0.002998 %	785	0.002998 %	- $
Manulife Investment Management Ltd. 0.000454 %	119	0.000454 %	- $
Bhirud Associates, Inc. 0.000191 %	50	0.000191 %	- $

Company contact information

EPIRUS Biopharmaceuticals, Inc.

699 Boylston Street 8th floor

02116, Boston

+617-600-3497

address Zalicus Inc

Sector

		Healthcare
			Pharmaceuticals & Medical Research
				Biotechnology & Medical Research
					Biotechnology & Medical Research
						Other Biotechnology & Medical Research

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-0.02%	42.11B
LONZA GROUP AG	+46.23%	40.08B
MODERNA, INC.	+5.04%	40B
CELLTRION, INC.	-11.32%	26.87B
ICON PUBLIC LIMITED COMPANY	+5.25%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.83%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.94B
MEDPACE HOLDINGS, INC.	+22.75%	11.66B
UNITED THERAPEUTICS CORPORATION	+6.44%	11.01B

Other Biotechnology & Medical Research

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer